BRCA1 and ovarian carcinoma: NCT02571725 is a phase I/II study of olaparib at a dose of 300 mg twice a day (bis in die—BID), in combination with tremelimumab at a dose of 10 mg/kg monthly, for the treatment of BRCA1/2 mutated recurrent ovarian cancer [52].